María José Méndez-Vidal
A5103041605- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
Hospital Universitario Reina Sofía
2023-2025
Instituto Maimónides de Investigación Biomédica de Córdoba
2023-2024
Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) programmed cell death ligand-1 (PD-L1) inhibition in this disease. In study, the combination of savolitinib (MET inhibitor) durvalumab (PD-L1 investigated.This single-arm phase II trial explored (1,500 mg once every four weeks) (600 daily; ClinicalTrials.gov identifier: NCT02819596). Treatment-naïve or...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
444 Background: Phase II data from the CALYPSO study (NCT02819596) has shown activity for durvalumab (PD-L1 inhibitor) plus savolitinib (MET (D+S) in MET-driven advanced papillary renal cancer (aPRC), resulting ongoing randomised phase III study, SAMETA (NCT03091192). Here we present final efficacy and new ctDNA analysis. Methods: The aPRC cohort was a single arm of D+S both untreated previously treated disease. Efficacy endpoints include response rates (RR) as per RECIST 1.1,...
143 Background: In ARASENS, darolutamide (DARO) + ADT docetaxel (DOC) significantly reduced the risk of death by 32.5% (HR 0.68; 95% CI 0.57–0.80; P <0.0001) vs placebo (PBO) DOC with similar incidence treatment-emergent adverse events (TEAEs) between groups in patients (pts) mHSPC. DARO has become one standards care We report post-hoc efficacy and safety pts age subgroups (<75 y, ≥75 y) ARASENS. Methods: Pts were randomized to receive 600 mg orally twice daily or PBO, DOC. Age...
Renal cancer is the seventh most common in men and tenth women. The aim of this article to review diagnosis, treatment, follow-up renal carcinoma accompanied by recommendations with new evidence treatment algorithms. A pathologic classification RCC World Health Organization (WHO) was published 2022 would be considered a "bridge" future molecular classification. For patients localized disease, surgery choice nephron-sparing recommended when feasible. Adjuvant pembrolizumab an option for...